Overview

Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to determine a maximum tolerated dose and to evaluate the safety and efficacy of CP-461 in patients with Chronic Lymphocytic Leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborators:
Cell Pathways
OSI Pharmaceuticals